DK1897548T3 - T-celleregulering - Google Patents
T-cellereguleringInfo
- Publication number
- DK1897548T3 DK1897548T3 DK07021595T DK07021595T DK1897548T3 DK 1897548 T3 DK1897548 T3 DK 1897548T3 DK 07021595 T DK07021595 T DK 07021595T DK 07021595 T DK07021595 T DK 07021595T DK 1897548 T3 DK1897548 T3 DK 1897548T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell regulation
- regulation
- cell
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45103903P | 2003-02-28 | 2003-02-28 | |
US48214303P | 2003-06-24 | 2003-06-24 | |
US53170403P | 2003-12-22 | 2003-12-22 | |
EP04716126A EP1596871A4 (en) | 2003-02-28 | 2004-03-01 | REGULATION BY LYMPHOCYTES T |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1897548T3 true DK1897548T3 (da) | 2013-11-18 |
Family
ID=32966451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07021595T DK1897548T3 (da) | 2003-02-28 | 2004-03-01 | T-celleregulering |
Country Status (13)
Country | Link |
---|---|
US (7) | US20060240024A1 (da) |
EP (4) | EP1596871A4 (da) |
JP (7) | JP2006523226A (da) |
AU (1) | AU2004217526B2 (da) |
CA (1) | CA2517287C (da) |
CY (1) | CY1114755T1 (da) |
DK (1) | DK1897548T3 (da) |
ES (1) | ES2439580T3 (da) |
HK (1) | HK1114339A1 (da) |
PL (1) | PL1897548T3 (da) |
PT (1) | PT1897548E (da) |
SI (1) | SI1897548T1 (da) |
WO (1) | WO2004078928A2 (da) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111415707A (zh) * | 2020-03-10 | 2020-07-14 | 四川大学 | 临床个体化肿瘤新抗原的预测方法 |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1596871A4 (en) | 2003-02-28 | 2006-08-23 | Drew M Pardoll | REGULATION BY LYMPHOCYTES T |
WO2006044864A2 (en) * | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
DK1928492T3 (da) * | 2005-09-01 | 2011-06-06 | Celgene Corp | Immunologiske anvendelser af immunmodulatoriske forbindelser til vaccine og terapi mod infektionssygdomme |
WO2007130555A2 (en) * | 2006-05-02 | 2007-11-15 | Providence Health System | Augmentation of immune response to cancer vaccine |
JPWO2008126940A1 (ja) * | 2007-04-10 | 2010-09-24 | 国立大学法人 東京大学 | 新規t細胞 |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP2264071A4 (en) * | 2008-03-14 | 2011-05-04 | Medinet Co Ltd | ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION |
CN102046780A (zh) * | 2008-03-27 | 2011-05-04 | 宝生物工程株式会社 | 转染的细胞的生产方法 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
US20120100160A1 (en) * | 2008-11-26 | 2012-04-26 | Immune Disease Institute | Methods for Inducing Mixed Chimerism |
ES2694749T3 (es) | 2011-06-30 | 2018-12-27 | Genzyme Corporation | Inhibidores de la activación de células T |
WO2013063504A1 (en) * | 2011-10-26 | 2013-05-02 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
JP2016507520A (ja) | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 安定化されたb型肝炎コアポリペプチド |
EP2970909A4 (en) | 2013-03-15 | 2017-02-15 | The University of Chicago | Methods and compositions related to t-cell activity |
JP6224739B2 (ja) | 2013-03-15 | 2017-11-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 抗lag−3結合タンパク質 |
ES2728578T3 (es) | 2013-09-20 | 2019-10-25 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores |
WO2015048312A1 (en) * | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2015089114A1 (en) * | 2013-12-09 | 2015-06-18 | Bullet Biotechnology, Inc. | Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3338800A1 (en) * | 2014-02-21 | 2018-06-27 | IDAC Theranostics, Inc. | Therapeutic agent for solid cancer |
PT3116909T (pt) * | 2014-03-14 | 2020-01-30 | Novartis Ag | Moléculas de anticorpos para lag-3 e suas utilizações |
NZ726513A (en) | 2014-05-28 | 2023-07-28 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
EP4029508A1 (en) | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
TN2017000129A1 (en) | 2014-10-14 | 2018-10-19 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-l1 and uses thereof |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
TWI702290B (zh) * | 2015-04-07 | 2020-08-21 | 富禾生醫股份有限公司 | 經修飾之自然殺手t細胞、醫藥組合物及其用途 |
EA039293B1 (ru) * | 2015-06-05 | 2021-12-30 | Мерк Шарп И Доум Корп. | Антитела против lag3 и антигенсвязывающие фрагменты |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
AU2016293101B2 (en) | 2015-07-15 | 2022-06-16 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for LAG-3 |
EP3328419B1 (en) | 2015-07-30 | 2021-08-25 | MacroGenics, Inc. | Pd-1-binding molecules and methods of use thereof |
AU2016303497A1 (en) * | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
AU2016316730B2 (en) | 2015-09-02 | 2023-05-25 | Immutep S.A.S. | Anti-LAG-3 Antibodies |
KR102146319B1 (ko) | 2015-10-02 | 2020-08-25 | 에프. 호프만-라 로슈 아게 | Pd1 및 tim3에 특이적인 이중특이성 항체 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
RS61866B1 (sr) * | 2015-11-20 | 2021-06-30 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za aktivaciju limfocita 3 |
AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
AU2016371639A1 (en) | 2015-12-16 | 2018-06-28 | Merck Sharp & Dohme Llc | Anti-LAG3 antibodies and antigen-binding fragments |
JP7137474B2 (ja) | 2016-03-15 | 2022-09-14 | メルサナ セラピューティクス,インコーポレイティド | NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法 |
MX2018016364A (es) | 2016-06-20 | 2019-11-28 | Kymab Ltd | Anticuerpos anti-pd-l1. |
JP6998895B2 (ja) | 2016-06-23 | 2022-01-18 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Lag-3抗体、その抗原結合フラグメント、およびそれらの医薬的用途 |
RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
EA039718B1 (ru) * | 2016-07-21 | 2022-03-03 | Регенерон Фармасьютикалз, Инк. | Антитела к lag3 и их применения |
WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
CN108070613B (zh) | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018086583A1 (en) * | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric lag-3 |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
CN110402252A (zh) | 2017-01-18 | 2019-11-01 | 皮里斯制药有限公司 | 对lag-3具有结合亲和力的脂质运载蛋白突变蛋白 |
EP3580238A1 (en) | 2017-02-10 | 2019-12-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
WO2018160538A1 (en) | 2017-02-28 | 2018-09-07 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
PE20191494A1 (es) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15 |
CN116375876A (zh) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
MA49034B1 (fr) | 2017-04-05 | 2022-09-30 | Hoffmann La Roche | Anticorps anti-lag3 |
EP3630179A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
CA3060984A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
JP7416629B2 (ja) * | 2017-06-16 | 2024-01-17 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 免疫応答を増強するための物質および方法 |
EP3652212A4 (en) * | 2017-07-13 | 2021-04-14 | Nanjing Leads Biolabs Co., Ltd. | LAG-3 BINDING ANTIBODIES AND USES THEREOF |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US20220305127A1 (en) | 2017-12-21 | 2022-09-29 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
KR20200104314A (ko) * | 2017-12-22 | 2020-09-03 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Lag-3 항체 약학 조성물 및 이의 용도 |
JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス, インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
WO2019149716A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
EP3873534A1 (en) | 2018-10-29 | 2021-09-08 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
CN111304247B (zh) | 2018-12-20 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | 人源化lag-3基因改造动物模型的制备方法及应用 |
CN109666699B (zh) * | 2018-12-29 | 2023-02-28 | 杭州科兴生物科技有限公司 | 一种基于lag-3/mhc ii阻断功能及其生物效应的药物快速筛选方法 |
JP2022529947A (ja) * | 2019-04-16 | 2022-06-27 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ドナーアポトーシス白血球が誘導する移植免疫寛容のバイオマーカー |
MX2021013815A (es) | 2019-05-13 | 2021-12-14 | Regeneron Pharma | Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer. |
CN114605544B (zh) * | 2020-06-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | Lag3抗体及其用途 |
JP2022176672A (ja) * | 2021-05-17 | 2022-11-30 | 国立大学法人北海道大学 | ペプチド及び医薬用組成物 |
WO2022245816A1 (en) * | 2021-05-18 | 2022-11-24 | Pelican Therapeutics, Inc. | Treatment of autoimmune inflammatory diseases with tnfrsf25-binding agents |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5976877A (en) * | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
KR100257466B1 (ko) | 1994-05-06 | 2000-07-01 | 레지날드 쇼트버그 에스. 안토니우스-소도 | Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체 |
CA2227334A1 (en) * | 1995-07-21 | 1997-02-06 | Applied Research Systems Ars Holding N.V. | Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein |
AU726198B2 (en) | 1996-03-04 | 2000-11-02 | Targeted Genetics Corporation | Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes |
EP0904350B1 (en) * | 1996-03-04 | 2010-08-04 | Calyx Bio-Ventures Inc. | Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes |
WO1998023741A1 (fr) * | 1996-11-28 | 1998-06-04 | Institut Gustave Roussy | Mutants de la proteine lag-3, leur expression et utilisation |
CN1196786C (zh) * | 1996-11-29 | 2005-04-13 | 应用研究系统Ars股份公司 | 抗移植排斥细胞及其用途 |
EP0941329B1 (en) * | 1996-11-29 | 2004-07-21 | Applied Research Systems ARS Holding N.V. | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) |
EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
JPH1164707A (ja) * | 1997-08-13 | 1999-03-05 | Fuji Photo Optical Co Ltd | ズームレンズ鏡筒 |
US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
AU2002309873B2 (en) | 2001-05-15 | 2007-10-18 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer |
AU2002344237B8 (en) * | 2001-05-29 | 2008-11-06 | Sirna Therapeutics, Inc. | Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions |
JP4460282B2 (ja) * | 2001-06-12 | 2010-05-12 | バイエル・クロップサイエンス・アーゲー | 高アミロースデンプンを合成するトランスジェニック植物 |
CA2936534C (en) * | 2001-07-23 | 2021-01-26 | The Board Of Trustees Of Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
EP1596871A4 (en) | 2003-02-28 | 2006-08-23 | Drew M Pardoll | REGULATION BY LYMPHOCYTES T |
CA2530285C (en) | 2003-06-27 | 2019-12-24 | Abgenix, Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
TWI468417B (zh) * | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
-
2004
- 2004-03-01 EP EP04716126A patent/EP1596871A4/en not_active Withdrawn
- 2004-03-01 SI SI200432110T patent/SI1897548T1/sl unknown
- 2004-03-01 AU AU2004217526A patent/AU2004217526B2/en not_active Expired
- 2004-03-01 DK DK07021595T patent/DK1897548T3/da active
- 2004-03-01 EP EP20070021595 patent/EP1897548B1/en not_active Expired - Lifetime
- 2004-03-01 CA CA2517287A patent/CA2517287C/en not_active Expired - Lifetime
- 2004-03-01 WO PCT/US2004/006133 patent/WO2004078928A2/en active Application Filing
- 2004-03-01 EP EP20130179162 patent/EP2659893A3/en not_active Withdrawn
- 2004-03-01 ES ES07021595T patent/ES2439580T3/es not_active Expired - Lifetime
- 2004-03-01 EP EP18177034.8A patent/EP3427741A3/en active Pending
- 2004-03-01 PL PL07021595T patent/PL1897548T3/pl unknown
- 2004-03-01 JP JP2006508934A patent/JP2006523226A/ja not_active Withdrawn
- 2004-03-01 PT PT70215959T patent/PT1897548E/pt unknown
- 2004-03-01 US US10/547,371 patent/US20060240024A1/en not_active Abandoned
-
2008
- 2008-09-08 HK HK08109961A patent/HK1114339A1/xx not_active IP Right Cessation
-
2009
- 2009-10-22 US US12/578,887 patent/US8551481B2/en active Active
-
2010
- 2010-11-12 JP JP2010253326A patent/JP2011116755A/ja not_active Withdrawn
-
2012
- 2012-11-16 US US13/679,485 patent/US9005629B2/en active Active
-
2013
- 2013-10-18 JP JP2013217056A patent/JP2014058523A/ja not_active Withdrawn
- 2013-11-14 CY CY20131101011T patent/CY1114755T1/el unknown
- 2013-12-13 US US14/105,293 patent/US20140127226A1/en not_active Abandoned
-
2015
- 2015-12-18 US US14/973,806 patent/US10787513B2/en active Active
-
2016
- 2016-04-13 JP JP2016080113A patent/JP2016169216A/ja not_active Withdrawn
-
2017
- 2017-07-24 JP JP2017142742A patent/JP6758259B2/ja not_active Expired - Lifetime
-
2018
- 2018-03-30 US US15/942,168 patent/US10934354B2/en not_active Expired - Lifetime
-
2019
- 2019-04-05 JP JP2019072698A patent/JP2019135247A/ja not_active Withdrawn
-
2021
- 2021-01-22 US US17/155,228 patent/US20210230275A1/en not_active Abandoned
- 2021-12-28 JP JP2021214040A patent/JP2022034067A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111415707A (zh) * | 2020-03-10 | 2020-07-14 | 四川大学 | 临床个体化肿瘤新抗原的预测方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1897548T3 (da) | T-celleregulering | |
DE50310628D1 (de) | Erfahren | |
ATE363383T1 (de) | Schlingenware | |
DE502004001683D1 (de) | Kabelführung | |
FI6928U1 (fi) | Peliautomaatti | |
AT502792A5 (de) | Düsenanpressvorrichtung | |
DE112004000620D2 (de) | Struktoguss | |
DE502004000672D1 (de) | Pigmentpreparationen | |
DE502004001524D1 (de) | Hydrolager | |
ATE446959T1 (de) | Chromenonindole | |
DE502004001629D1 (de) | Bremsenprüfstand | |
DE502004003122D1 (de) | Hydrolager | |
DE502004002978D1 (de) | N-biarylamide | |
DE502004000518D1 (de) | Mitgängergabelhubwagen | |
DE502004006563D1 (de) | Brieftaubenkonstatiersystem | |
DE10394329D2 (de) | Mäanderstent | |
DE10355350A8 (de) | Elektromodul | |
DE502004005162D1 (de) | Leistungsregelvorricthung | |
ATE406350T1 (de) | Prolinylarylacetamide | |
DE112004002227D2 (de) | Nietverarbeitungsgerät | |
DE10329218B4 (de) | Hotflue | |
DE112004002110D2 (de) | Behälter-Deckel-Kombination | |
DE112004001561D2 (de) | Getriebene-Antreibseinheit | |
DE502004007251D1 (de) | En 2-arylpropenalen | |
DE502004004175D1 (de) | Verbrennungskraftmaschime |